CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 51 enrolled
Drug / intervention
MitraClip proceduredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04259411
NCT04259411N/ACompleted
CompareCT.gov

A Prospective, Multi-Center, Single-Arm, Post Market Study of the MitraClip System for the Treatment of Symptomatic Mitral Regurgitation in China

Abbott Medical Devices·interventional·Posted Feb 6, 2020·Updated Dec 15, 2025

In Brief

A clinical study evaluating MitraClip procedure for Mitral Regurgitation. Completed, enrolled 51 participants across 5 sites.

Detailed Summary

The MitraClip System is the first commercially available catheter-based option for the treatment of MR. The MitraClip System was developed as an alternate percutaneous technology which may serve as a viable therapeutic option for open-heart surgery. Treatment with the MitraClip device allows patients to undergo a less invasive procedure that can mechanistically reduce MR and allow for improved quality of life. The MitraClip procedure is performed under general anesthesia without the use of a heart-lung machine, with recovery typically lasting two to three days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMitral Regurgitation
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 6, 2020
Enrollment StartDec 6, 2021
Primary CompletionMay 29, 2024
Study CompletionMar 7, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.4 years ago

Interventions

MitraClip proceduredevice

MitraClip procedure with MitraClip NTR System or MitraClip XTR System